MOLECULAR THERAPY

Scope & Guideline

Unleashing the potential of molecular mechanisms for healing.

Introduction

Welcome to your portal for understanding MOLECULAR THERAPY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1525-0016
PublisherCELL PRESS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2000 to 2024
AbbreviationMOL THER / Mol. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139

Aims and Scopes

Molecular Therapy is a journal dedicated to advancing the understanding and application of molecular therapeutics in various fields of medicine, particularly cancer, immunotherapy, and regenerative medicine. The journal aims to publish high-quality research that contributes to the development of novel therapeutic strategies and approaches.
  1. Cancer Therapeutics and Immunotherapy:
    The journal focuses on novel approaches to cancer treatment, including immunotherapy strategies such as engineered T cells and bispecific antibodies, as well as small molecule inhibitors targeting specific pathways related to tumor growth and metastasis.
  2. Metabolic and Inflammatory Disorders:
    Research on the therapeutic effects of various compounds in metabolic and inflammatory conditions is prominent, emphasizing the role of natural products, dietary components, and synthetic compounds in modulating metabolic pathways and inflammatory responses.
  3. Neuroprotection and Neuroinflammation:
    The journal includes studies on neuroprotective agents and the mechanisms underlying neuroinflammation, particularly in relation to neurodegenerative diseases and brain injuries.
  4. Molecular Mechanisms of Drug Action:
    A significant focus is placed on elucidating the molecular mechanisms of action of various therapeutic agents, including their effects on signaling pathways, gene expression, and cellular processes.
  5. Natural Products and Traditional Medicine:
    The exploration of bioactive compounds derived from natural sources for their therapeutic potentials is a key area, with studies investigating their mechanisms of action and clinical applications.
Recent publications in Molecular Therapy indicate several emerging themes that are gaining traction within the research community. These trends reflect current scientific interests and the evolving landscape of therapeutic development.
  1. Engineered Cell Therapies:
    There is a growing focus on engineered cell therapies, particularly in cancer treatment. This includes advancements in T cell receptor engineering and bispecific antibodies, which highlight innovative approaches to enhancing immune responses against tumors.
  2. Microbiome and Gut-Brain Axis:
    Research examining the role of gut microbiota and their metabolites in brain function and pathology is emerging, reflecting an interdisciplinary approach that links microbiology, neuroscience, and therapeutic interventions.
  3. Natural Compounds in Therapy:
    An increasing number of studies are investigating the therapeutic potentials of natural compounds, emphasizing their roles in modulating complex biological pathways and their potential applications in treating various diseases.
  4. Signaling Pathways in Disease Modulation:
    A trend towards understanding the intricate signaling pathways involved in disease mechanisms is evident, with a focus on how these pathways can be targeted for therapeutic intervention.
  5. Personalized Medicine Approaches:
    Emerging themes include the development of personalized medicine strategies, particularly in cancer therapeutics, where individual genetic and molecular profiles guide treatment decisions.

Declining or Waning

While Molecular Therapy continues to explore a wide range of impactful research areas, certain themes have shown a decline in prominence over recent years. This may reflect shifts in research focus or advancements in related fields.
  1. Traditional Pharmacology:
    Research centered around traditional pharmacological approaches has decreased, possibly due to the growing interest in novel molecular mechanisms and targeted therapies that offer more precise and effective treatment options.
  2. Basic Biochemical Studies:
    There is a noted reduction in purely biochemical studies that do not directly relate to therapeutic applications. The journal appears to favor research with clear clinical implications or translational potential.
  3. Animal Models of Disease:
    Although animal studies remain important, there seems to be a waning emphasis on basic animal model research without direct therapeutic relevance, as the focus shifts towards more innovative and applicable therapeutic strategies.

Similar Journals

JOURNAL OF MOLECULAR MEDICINE-JMM

Championing High-Quality Research in Biomedical Science.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Molecular & Cellular Oncology

Unraveling the complexities of cancer biology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Anti-Cancer Agents in Medicinal Chemistry

Empowering researchers with cutting-edge insights in oncology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

CELLULAR ONCOLOGY

Pioneering Open Access Discoveries in Cellular Oncology
Publisher: SPRINGERISSN: 2211-3428Frequency: 6 issues/year

CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

Discovery Medicine

Fostering a vibrant dialogue in the world of medical sciences.
Publisher: DISCOVERY MEDICINEISSN: 1539-6509Frequency: 6 issues/year

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

Molecular Therapy Oncolytics

Empowering Researchers to Revolutionize Cancer Therapy
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

CANCER GENE THERAPY

Innovating Genetic Solutions for Oncology
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Frontiers in Bioscience-Landmark

Driving Impactful Research in the Biosciences
Publisher: IMR PRESSISSN: 2768-6701Frequency: 12 issues/year

Frontiers in Bioscience-Landmark is a prestigious journal published by IMR PRESS that focuses on a diverse array of topics within the fields of biochemistry, genetics, molecular biology, immunology, and microbiology. With the ISSN 2768-6701 and E-ISSN 2768-6698, this journal has carved a significant niche since its inception in 1996, making its mark in contributions to the scientific community all the way through to 2024. Having achieved a respectable Q2 cohort rank in multiple categories, including biochemistry and immunology, it stands out for its impactful research, evidenced by its current Scopus rankings which highlight it as a vital resource for ongoing studies and advancements in the biosciences. Despite not being open access, the journal ensures that readers have access to high-quality research articles that are peer-reviewed and designed to foster academic discourse. The importance of Frontiers in Bioscience-Landmark lies in its commitment to disseminating innovative findings that can significantly enhance our understanding of biological sciences, making it an essential read for researchers, professionals, and students alike.

Biomolecules & Therapeutics

Connecting Researchers to Shape the Future of Medicine
Publisher: KOREAN SOC APPLIED PHARMACOLOGYISSN: 1976-9148Frequency: 4 issues/year

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

JOURNAL OF GENE MEDICINE

Exploring the Future of Genetic Innovation
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.